Pfizer Chooses Chesterfield, Missouri, For Research-Development Complex
05/31/2019
The site will house Pfizer’s BioTherapeutics Pharmaceutical Sciences group and enable partners to advance Pfizer’s biologics, vaccines and gene therapy portfolio.
“The Chesterfield site is an important expansion of our R&D capabilities and is designed to support the development of potential new medicines and vaccines,” said Mikael Dolsten, M.D., Ph.D., Pfizer Chief Scientific Officer & President, Worldwide Research, Development and Medical. “Together, we will attempt to accelerate scientific breakthroughs and realize our commitment to patients to transform their lives.”
According to company officials, the facility brings together around 450 existing Pfizer colleagues and provides more than 80 new positions in Chesterfield. It offers new state-of-the-art features, including flexible laboratory layouts and open floor plans to encourage collaboration across functions and colleagues, including engineers, biologists, biochemists, analytical chemists and pharmacy specialists.
Pfizer’s new site will develop manufacturing processes, dosage forms and analytics to deliver clinical and commercial supplies with industry-leading speed and quality in a variety of therapeutic areas including oncology, rare disease, internal medicine, inflammation & immunology, and vaccines, including biosimilars.
It will also enable the manufacturing of plasmids for gene therapy clinical supplies as well as work to develop innovative gene therapy manufacturing technologies and solutions.
“We are pleased that Pfizer has chosen to invest in Missouri and grow its presence here within the life sciences community in the Midwest,” Governor Mike Parson said. “This is an important facility that will benefit the Chesterfield community and help improve the lives of many Missourians as well as patients around the world.”
“Pfizer’s choice of St. Louis County for this new facility is a testament to our skilled workforce as well as our growing international reputation as a center for research in the biopharma, plant science and information technology fields,” St. Louis County Executive Sam Page said. “The company’s investment in this expansion is one of the largest in the history of St. Louis County. But beyond the economic benefit for our region, the focus of Pfizer’s research and development work here will save lives and relieve suffering around the world.”
The opening of the Chesterfield facility comes days after the opening of Pfizer’s new 175,000 square-foot manufacturing facility in Andover, Massachusetts. Pfizer’s Andover site houses clinical and commercial manufacturing and product development functions, with colleagues dedicated to the development and production of high-quality complex biologics and vaccines.
Project Announcements
PEAK Precision Manufacturing Plans Bowling Green, Kentucky, Operations
07/26/2024
Italy-Based Sipcam Agro USA Upgrades Wayne County, Mississippi, Operations
07/26/2024
Cleveland-Cliffs Plans Weirton, West Virginia, Operations
07/26/2024
IDEXX Laboratories Plans Wilson, North Carolina, Production Operations
07/26/2024
Germany-Based Ritz Instrument Transformers Plans Waynesboro, Georgia, Operations
07/26/2024
AirJoule Plans Newark-Wilmington, Delaware, Operations
07/26/2024
Most Read
-
19th Annual Area Development Gold and Silver Shovel Awards
Q2 2024
-
2023's Leading Metro Locations: Hotspots of Economic Growth
Q4 2023
-
2023 Top States for Doing Business Meet the Needs of Site Selectors
Q3 2023
-
The CHIPS and Science Act will bring jobs back to the United States
Q2 2024
-
2023 Top States Commentary: Top-Ranked States Have What It Takes to Win Mega Projects
Q3 2023
-
The Bring Your Own Energy (BYOE) Party Is Starting
Q2 2024
-
Midwest becomes hotspot for semiconductor manufacturing and supply industries
Q2 2024